Treatment With Mifepristone Allows a Patient With End-stage Pancreatic Cancer in Hospice on a Morphine Drip to Restore a Decent Quality of Life
| Autor: | Maya D Srivastava, Diane Check, Jerome H. Check, Trina Poretta, James Aikins |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Drug Oncology Cancer Research medicine.medical_specialty media_common.quotation_subject 03 medical and health sciences Hormone Antagonists 0302 clinical medicine Quality of life Internal medicine Pancreatic cancer Progesterone receptor medicine Humans Stage (cooking) media_common Experimental drug Morphine business.industry General Medicine Mifepristone Middle Aged medicine.disease Survival Analysis Analgesics Opioid Pancreatic Neoplasms 030220 oncology & carcinogenesis Quality of Life business medicine.drug |
| Zdroj: | Anticancer Research. 40:6997-7001 |
| ISSN: | 1791-7530 0250-7005 |
| Popis: | Background There is evidence that a unique immunomodulatory protein, known as the progesterone induced blocking factor (PIBF), is utilized by a large variety of cancers to escape immune surveillance. Mifepristone, a progesterone receptor antagonist/modulator, anecdotally, has been found to increase both length and quality of life in many different types of advanced cancers. Case report Though there was one previous case of pancreatic cancer that showed a significant reduction in pain for the one month she took mifepristone before changing to an experimental drug, the case presented here provided much greater evidence that this drug can markedly improve both length and quality of life, in at least some patients, with very advanced pancreatic cancer. Conclusion It is hoped that this case report will influence others to prescribe mifepristone off-label and hopefully substantiate this finding of marked palliative benefit in the majority of a larger series of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|